Tummers Quirijn R J G, Hoogstins Charlotte E S, Peters Alexander A W, de Kroon Cor D, Trimbos J Baptist M Z, van de Velde Cornelis J H, Frangioni John V, Vahrmeijer Alexander L, Gaarenstroom Katja N
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands.
PLoS One. 2015 Jun 25;10(6):e0129766. doi: 10.1371/journal.pone.0129766. eCollection 2015.
In ovarian cancer, two of the most important prognostic factors for survival are completeness of staging and completeness of cytoreductive surgery. Therefore, intra-operative visualization of tumor lesions is of great importance. Preclinical data already demonstrated tumor visualization in a mouse-model using near-infrared (NIR) fluorescence imaging and indocyanine green (ICG) as a result of enhanced permeability and retention (EPR). The aim of this study was to determine feasibility of intraoperative ovarian cancer metastases imaging using NIR fluorescence imaging and ICG in a clinical setting.
Ten patients suspected of ovarian cancer scheduled for staging or cytoreductive surgery were included. Patients received 20 mg ICG intravenously after opening the abdominal cavity. The mini-FLARE NIR fluorescence imaging system was used to detect NIR fluorescent lesions.
6 out of 10 patients had malignant disease of the ovary or fallopian tube, of which 2 had metastatic disease outside the pelvis. Eight metastatic lesions were detected in these 2 patients, which were all NIR fluorescent. However, 13 non-malignant lesions were also NIR fluorescent, resulting in a false-positive rate of 62%. There was no significant difference in tumor-to-background ratio between malignant and benign lesions (2.0 vs 2.0; P=0.99).
This is the first clinical trial demonstrating intraoperative detection of ovarian cancer metastases using NIR fluorescence imaging and ICG. Despite detection of all malignant lesions, a high false-positive rate was observed. Therefore, NIR fluorescence imaging using ICG based on the EPR effect is not satisfactory for the detection of ovarian cancer metastases. The need for tumor-specific intraoperative agents remains.
ISRCTN Registry ISRCTN16945066.
在卵巢癌中,生存的两个最重要的预后因素是分期的完整性和肿瘤细胞减灭术的完整性。因此,术中对肿瘤病灶的可视化非常重要。临床前数据已证明,在小鼠模型中使用近红外(NIR)荧光成像和吲哚菁绿(ICG),由于增强的通透性和滞留(EPR)效应可实现肿瘤可视化。本研究的目的是确定在临床环境中使用NIR荧光成像和ICG进行术中卵巢癌转移灶成像的可行性。
纳入10例计划进行分期或肿瘤细胞减灭术的疑似卵巢癌患者。打开腹腔后,患者静脉注射20mg ICG。使用mini-FLARE NIR荧光成像系统检测NIR荧光病灶。
10例患者中有6例患有卵巢或输卵管恶性疾病,其中2例在盆腔外有转移病灶。在这2例患者中检测到8个转移病灶,均为NIR荧光阳性。然而,13个非恶性病灶也呈NIR荧光阳性,假阳性率为62%。恶性和良性病灶之间的肿瘤与背景比值无显著差异(2.0对2.0;P=0.99)。
这是第一项使用NIR荧光成像和ICG进行术中检测卵巢癌转移灶的临床试验。尽管检测到了所有恶性病灶,但观察到较高的假阳性率。因此,基于EPR效应使用ICG的NIR荧光成像对于检测卵巢癌转移灶并不令人满意。仍然需要肿瘤特异性的术中试剂。
ISRCTN注册中心ISRCTN16945066。